VEA
MRKR icon

Virtus ETF Advisers’s Marker Therapeutics MRKR Stock Holding History

Virtus ETF Advisers’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,967
Closed -$262K – 445
2019
Q1 		$262K Sell
3,967
-529
-12% -$30.9K 0.56% 73
2018
Q4 		$250K Buy
+4,496
New +$328K 0.04% 160

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus ETF Advisers's MRKR Position: Q2 2019 in Review

Virtus ETF Advisers sold out of Marker Therapeutics (MRKR) in Q2 2019, closing a stake of 3,967 shares — an estimated $262K sold.

Virtus ETF Advisers first reported a position in MRKR in Q4 2018 and held it in 2 quarters. The position peaked at $262K in Q1 2019. 70 funds tracked by Wall St. Rank hold MRKR as of Q2 2019.

  • Virtus ETF Advisers reported no remaining Marker Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,967 Marker Therapeutics shares in Q2 2019, an estimated $262K.
  • Virtus ETF Advisers first reported a position in Marker Therapeutics in Q4 2018 and held it in 2 quarters.
  • Virtus ETF Advisers's Marker Therapeutics position peaked at $262K in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2019.

Based on Virtus ETF Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.